Granted Patent
B2
US 12,569,475 · App. 18/532,876 · Granted Mar 10, 2026
Method for eradicating helicobacter pylori infection in patients regardless of body mass index
Assignee:
RedHill Biopharma Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A method of treating patients who are positive for Helicobacter pylori infection comprises determining that a first patient who is positive for Helicobacter pylori infection has a body mass index corresponding to normal weight or overweight; determining that a second patient who is positive for Helicobacter pylori infection has a body mass index corresponding to obese or extremely obese; and administering to both the first patient and the second patient, for 14 days, a rifabutin-based triple therapy consisting essentially of rifabutin, amoxicillin and omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof, wherein, after treatment is complete, there is no substantial difference in the efficacy of the treatment when the treatment is administered to the first patient or the second patient.
Claims (27)
1 . A method of treating patients who are positive for Helicobacter pylori infection comprising:
determining that a first patient who is positive for Helicobacter pylori infection has a body mass index corresponding to normal weight or overweight;
determining that a second patient who is positive for Helicobacter pylori infection has a body mass index corresponding to obese or extremely obese; and
administering to both the first patient and the second patient, for 14 days three times a day with food, four fixed-dose combination formulations which provide a total daily dose of 150 mg rifabutin, 3,000 mg amoxicillin, and 120 mg omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof,
wherein each fixed-dose combination formulation comprises between 36 and 40 immediate release minitablets comprising both amoxicillin and rifabutin, and between 32 and 36 enteric-coated omeprazole minitablets, and
wherein, after treatment is complete, there is no substantial difference in the efficacy of the treatment when the treatment is administered to the first patient or the second patient.
2 . The method of claim 1 , wherein the first patient has a BMI ranging from 18.50 kg/m 2 to 24.99 kg/m 2 and the second patient has a BMI ranging from 30.0 kg/m 2 to 34.99 kg/m 2 .
3 . The method of claim 1 , wherein the first patient has a BMI ranging from 18.50 kg/m 2 to 24.99 kg/m 2 and the second patient has a BMI ranging from 35.0 kg/m 2 to 39.99 kg/m 2 .
4 . The method of claim 1 , wherein the first patient has a BMI ranging from 18.50 kg/m 2 to 24.99 kg/m 2 and the second patient has a BMI above 40.00 kg/m 2 .
5 . The method of claim 1 , wherein the first patient has a BMI ranging from 25.00 kg/m 2 to 29.99 kg/m 2 and the second patient has a BMI ranging from 35.0 kg/m 2 to 39.99 kg/m 2 .
6 . The method of claim 1 , wherein the first patient has a BMI 25.00 kg/m 2 to 29.99 kg/m 2 and the second patient has a BMI ranging from 30.0 kg/m 2 to 34.99 kg/m 2 .
7 . The method of claim 1 , wherein the first patient has a BMI 25.00 kg/m 2 to 29.99 kg/m 2 and the second patient has a BMI above 40.00 kg/m 2 .
8 . The method of claim 1 , wherein the administering to both the first patient and the second patient comprises taking four fixed-dose combination formulations every 8 hours, wherein each dose of four fixed-dose combination formulations includes 50 mg rifabutin, 1,000 mg amoxicillin and 40 mg omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof.
9 . The method of claim 1 , wherein each fixed-dose combination formulation comprises 12.5 mg rifabutin, 250 mg amoxicillin and 10 mg omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof.
10 . The method of claim 1 , wherein each fixed-dose combination formulation is a capsule.
11 . The method of claim 1 , wherein each fixed-dose combination formulation comprises a mixture of amoxicillin and rifabutin immediate release minitablets and enteric-coated omeprazole minitablets.
12 . The method of claim 11 , wherein the immediate release minitablets and the enteric-coated omeprazole minitablets are each about 2 mm in size.
13 . The method of claim 11 , wherein each fixed-dose combination formulation comprises 38 of the immediate release minitablets and 34 of the enteric-coated minitablets.
14 . The method of claim 1 , wherein at least 70% by weight of the omeprazole is intestinally released after oral administration.
15 . The method of claim 1 , wherein the amoxicillin is amoxicillin trihydrate.
16 . The method of claim 1 , wherein the omeprazole is omeprazole magnesium.
17 . The method of claim 1 , further comprising confirming H. pylori eradication with a negative 13 C UBT or fecal antigen test performed ≥28 days post-therapy.
18 . The method of claim 1 , wherein the second patient who tested positive for Helicobacter pylori infection is obese with a BMI above 30.00 kg/m 2 and is preparing for bariatric surgery.
19 . A method of treating Helicobacter pylori infection comprising:
determining that a patient is positive for Helicobacter pylori infection and has a body mass index corresponding to obese or extremely obese; and
administering to the patient for 14 days three times a day with food a rifabutin-based triple therapy comprising a plurality of fixed-dose combination formulations which provide a total daily dose of 150 mg rifabutin, 3,000 mg amoxicillin, and 120 mg omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof,
wherein each fixed-dose combination formulation comprises between 36 and 40 immediate release minitablets comprising both amoxicillin and rifabutin, and between 32 and 36 enteric-coated omeprazole minitablets.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 19, 2026
From: REDHILL BIOPHARMA LTD.
To: TALICIA HOLDINGS INC.
Reel/Frame 075714/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 1, 2025
From: FATHI, REZA; SHELDON, KELY LEE
To: REDHILL BIOPHARMA LTD.
Reel/Frame 072435/0671 →
Continuity (2)
References Cited (193)
US 5927500A
· Godfrey et al.
· 1999
[cited by applicant]
US 6136344A
· Depui et al.
· 2000
[cited by applicant]
US 6489317B1
· Borody
· 2002
[cited by applicant]
US 6605303B1
· Karehill et al.
· 2003
[cited by applicant]
US 9050263B2
· Fathi
· 2015
[cited by applicant]
US 9498445B2
· Fathi et al.
· 2016
[cited by applicant]
US 9603806B2
· Fathi et al.
· 2017
[cited by applicant]
US 20040213847A1
· Matharu et al.
· 2004
[cited by applicant]
US 20090028941A1
· Cowles et al.
· 2009
[cited by applicant]
US 20090220611A1
· Dargelas et al.
· 2009
[cited by applicant]
CN 101584681A
· 2009
[cited by applicant]
CN 101607086A
· 2009
[cited by applicant]
CN 101888828A
· 2010
[cited by applicant]
CN 102091084B
· 2012
[cited by applicant]
EP 1803450A1
· 2007
[cited by applicant]
JP 2000128779A
· 2000
[cited by applicant]
WO 1996024375A1
· 1996
[cited by applicant]
WO 9822117A1
· 1998
[cited by applicant]
WO 9840054A1
· 1998
[cited by applicant]
WO 2005048979A2
· 2005
[cited by applicant]
WO 2007077158A1
· 2007
[cited by applicant]
WO 2009017716A2
· 2009
[cited by applicant]
WO 200913884A1
· 2009
[cited by applicant]
Salcedo et al. (Treatment of Heliobacter pylori infection) (Year: 1998).
[cited by examiner]
Staying healthy (Probiotics may help to prevent diarrhea due to antibiotic use). (Year: 2012).
[cited by examiner]
Abdullahi et al., The Eradication of Helicobacter pylori is Affected by Body Mass Index (BMI); Apr. 29, 2008, Obes Surg (2008) 18:1450-1454.
[cited by applicant]
Hall II, “Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World”; Current Pharmaceutical Design, 2015, 21, 000-000, pp. 1-4.
[cited by applicant]
Heep et al., “Rifampin and Rifabutin Resistance Mechanism in Helicobacter pylori”; Antimicrobial Agents and Chemotherapy, Jun. 1999, vol. 43, No. 6, p. 1497-1499.
[cited by applicant]
Horne et al., “Experience with Rifabutin Replacing Rifampin in the Treatment of Tuberculosis”, Int J Tuberc Lung Dis. Nov. 2011; 15(11): 1485-i.
[cited by applicant]
Kao et al., “Helicobacter pylori eradication by low-dose rifabutin triple therapy (RHB-105) is unaffected by high body mass index”, GastroHep. 2021, 3: 426-434.
[cited by applicant]
Longo et al., “The effect of obesity on antibiotic treatment failure: a historical cohort study”, Pharmacoepidemiology and Drug Safety (2013), DOI: 10.1002/pds.3461.
[cited by applicant]
Shah et al., “Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure”, Expert Review of Gastroenterology & Hepatology, 2022, vol. 167, No. 4, pp. 3…
[cited by applicant]
Sullam, “Rifabutin Therapy for Disseminated
[cited by applicant]
Tissen et al., “Development of mini-tablets with 1 mm and 2 mm diameter”, 2011, International Journal of Pharmaceutics, vol. 416, pp. 164-170 (Year: 2011).
[cited by applicant]
Al-Dorzi et al., “Antibiotic therapy of pneumonia in the obese patient: dosing and delivery”, Current Opinion; 2014 Wolters Kluwer Health; Lippincourt Williams & Wilkins; www.co-infectiousdiseases.com.
[cited by applicant]
Barras et al., “Drug dosing in obese adults”, Australian Prescriber, vol. 40, No. 5: Oct. 2017.
[cited by applicant]
Cerqueira et al., “Cumulative Helicobacter pylori Eradication Therapy in Obese Patients Undergoing Gastric Bypass Surgery”, Clinical Research; Obes Surg (2013) 23: 145-149.
[cited by applicant]
Laudanno et al., “Helicobacter Pylori Eradication in Obese Patients Undergoing Bariatric Surgery”, AGA Abstracts, 2017, Sa1189; S-247.
[cited by applicant]
Lemus-Castellanos et al., “Population Pharmacokinetics of Clarithromycin in Mexican Hospitalized Patients with Respiratory Disease: Evidence for a Reduced Clearance”, Research Article, International Journal of Pharmacol…
[cited by applicant]
McCafferty et al., “Obesity: Scope, Lifestyle Interventions, and Medical Management”, Techniques in Vascular and Interventional Radiology, 2020.
[cited by applicant]
Meng et al., “Comprehensive Guidance for Antibiotic Dosing in Obese Adults”, Pharmacotherapy 2017;37 (11):1415-1431.
[cited by applicant]
Pintar et al., “The need for a patient-tailored Helicobacter pylori eradication protocol prior to bariatric surgery”, Journal of International Medical Research, 2018, vol. 46(7) 2696-2707.
[cited by applicant]
RedHill Biopharma Press Release, “RedHill Biopharma Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study's Positive Results”.
[cited by applicant]
RedHill Biopharma Press Release, “RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (Talicia) for H.pylor Infection”.
[cited by applicant]
RedHill Biopharma Press Release, “RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H.pylori Infection”.
[cited by applicant]
RedHill Biopharma Press Release, “RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA for H. pylori Infection”.
[cited by applicant]
“ERADICATE Hp2—Treating Helicobacter Pylori with RHB-105 Compared to Active Comparator (ERADICATE Hp2)”, Trial record 1 of 1 for: NCT03198507, U.S. National Library of Medicine, 2020 <<https://clinicaltrials.gov/ct2/sho…
[cited by applicant]
“ERADICATE Hp—Treating Helicobacter Pylori with RHB-105 (Eradicate Hp)”, Trial record 1 of 1 for: NCT01980095; U.S. National Library of Medicine, 2019 <<https://clinicaltrials.gov/ct2/show?NCT01980095?term=NCT01980095&d…
[cited by applicant]
“The impact of obesity on drug prescribing in primary care”, British Journal of General Practice, Oct. 2005, pp. 743-749.
[cited by applicant]
Yasgur, “Antibiotic Failure: A Weighty Issue in Patients with Obesity”, MPR, retrieved Apr. 27, 2020 <<https://www.empr.com/home/features/antibiotic-failure-a-weighty-issue-in-patients-with-obesity/>>.
[cited by applicant]
Sierra et al., “Ideal treatment for Helicobacter pylori: A systematic review”, Revista de Gastroenterologia de Mexico, 2014; 79(1): 28-49.
[cited by applicant]
D.A. Charkevich, “Farmakologiya”, Pharmacology textbook, 9th ed. 2006, p. 66.
[cited by applicant]
ERADICATE Hp—Treating Helicobacter Pylori with RHB-105 (ERADICATE Hp), ClinicalTrials.gov, NCT01980095, Nov. 8, 2013.
[cited by applicant]
ERADICATE Hp2—Treating Helicobacter Pylori with RHB-105 Compared to Active Comparator (ERADICATE Hp2), ClinicalTrials.gov, NCT03198507, Jun. 26, 2017.
[cited by applicant]
RedHill Biopharma Press Release; “RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H.pylori Infection”, Jun. 15, 2015.
[cited by applicant]
RedHill Biopharma Press Release; “RedHill Biopharma Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study's Positive Results”, Sep. 8, 2015.
[cited by applicant]
RedHill Biopharma Press Release, “RedHill Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA for H.pylori Infection”, Dec. 3, 2018.
[cited by applicant]
RedHill Biopharma Press Release, “RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (Talicia) for H. pylori Infection”, Jun. 15, 2017.
[cited by applicant]
Meng et al., “Comprehensive Guidance for Antibiotic Dosing in Obese Adults”, Pharmacotherapy, vol. 37, No. 11, 2017, pp. 1415-1431.
[cited by applicant]
Laudanno et al., “Helicobacter Pylori Eradication in Obese Patients Undergoing Bariatric Surgery”, Sa1189, AGA Abstracts 2017.
[cited by applicant]
Barrar et al., “Drug dosing in obese adults”; Australian Prescriber, vol. 40, No., 5, Oct. 2017, pp. 189-193.
[cited by applicant]
Yasgur, “Antibiotic Failure: A Weighty Issue in Patients with Obesity”, MPR, Jul. 1, 2013, pp. 1-5.
[cited by applicant]
Cerqueira et al., “Cumulative Helicobacter pylori Eradication Therapy in Obese Patients Undergoing Gastric Bypass Surgery”, Obes Surg (2013) 23: 145-149.
[cited by applicant]
Abdullahi et al., “The Eradication of Helicobacter pylori is Affected by Body Mass Index (BMI)”, Obes Surg (2008) 18: 1450-1454.
[cited by applicant]
Gibbs et al., “The impact of obesity on drug prescribing in primary care”, British Journal of General Practice, Oct. 2005, pp. 743-749.
[cited by applicant]
Extended European Search Report from European Patent Application No. 14751025.9 dated Sep. 13, 2016.
[cited by applicant]
Omerprazole Delayed-Release Capsules; Official Monographs/Omeprazole, USP 35, pp. 4113-4115; 2014 U.S. Pharmacopela National Formulay, Official Dec. 1, 2014 to Apr. 30, 2015.
[cited by applicant]
Abbreviated Drug Class Review: Proton Pump Inhibitors, VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel, Aug. 2006.
[cited by applicant]
Borody, T. J. et al., “Efficacy and saftey of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection”, Alimentary Pharmacology & Therapeutics 2005, p. 481-488.
[cited by applicant]
Krishna, G. et al., “Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men”, Current Medical Research and Opinion 2007, vol. 23 No. 3, p. 545-552.
[cited by applicant]
Lozniewski A. et al., “Gastric diffusion of antibiotics used against Helicobacter pylori”, International Journal of Antimicrobial Agents, 1998, p. 181-193.
[cited by applicant]
Goddard, Andrew F. et al., “In Vitro Assessment of Gastric Mucosal Transfer of Anti-Helicobacter Therapeutic Agents”, Antimicrobial Agents and Chemotherapy, Jun. 1997, p. 1246-1249.
[cited by applicant]
Mainz, Dagmar et al., “Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration”, Journal of Antimicrobial Chemotherapy 2002, 50, p. 699-706.
[cited by applicant]
Robinson, M., “Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors—overview and clinical implications”, Aliment Pharmacal. Ther. 2004, 20 (Suppl. 6), p. 1-10.
[cited by applicant]
AGA (American Gastroenterological Association), “American Gastroenterological Association Medical Position Statement: Evaluation of Dyspepsia”, Gastroenterology (2005), 129:1753-1755.
[cited by applicant]
Akada, Junko K. et al., “In Vitro Anti-Helicobacter pylori Activities of New Rifamycin Derivatives, KRM-1648 and KRM-1657”, Antimicrob Agents and Chemotherapy (1999), 43(5):1072 1076.
[cited by applicant]
Dr. Reddys Laboratories Inc., Amoxicillin Capsules and Amoxicillin Powder, for Suspension, Package Insert (May 2012).
[cited by applicant]
Apseloff, Glen M.D., “Severe neutropenia among healthy volunteers given rifabutin in clinical trials”, Clinical Pharmacology and Therapeutics (Dec. 2003), 74:591-592.
[cited by applicant]
Axon, A.T.R., “Campylobacter pylori-therapy review”, Scand. J. Gastroenterol (1989), 24 Suppl. 160:35-38.
[cited by applicant]
Axon, Anthony et al., “Helicobacter gastroduodenitis: a serious infectious disease”, British Medical Journal. (1997), 314:1430-1431.
[cited by applicant]
Barzilay, Ezra J., Chapter 3: Infectious Diseases Related to Travel, IN:2012 Yellow Book—Travelers' Health—CDC. (2011), New York: Oxford University Press Inc.
[cited by applicant]
Bazzoli, Franco et al., “Short-term low-dose triple therapy for the eradication of Helicobacter pylori”, Eur. J. Gastroenterol Hepatol. (1994), 6:773-777.
[cited by applicant]
Beales, Ian LP., “Efficacy of Helicobacter pylori eradication therapies: a single centre observational study”, BioMed Central, Gastroenterology (2001), 1:7.
[cited by applicant]
Behrens, Rolf et al., “Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial”, Arch Dis Child (Jul. 1999), 81:68-70.
[cited by applicant]
Bock, H. M.D. et al., “Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience”, J. Clin. Gastroenterol. (2000), 31:222-225.
[cited by applicant]
Borody, T.J et al., “Symptoms improve after the eradication of gastric Campylobacter pyloridis”, Medical J. Australia. (1987), 146:450-451.
[cited by applicant]
Borody, T.J. and Brandi S, Andrews P. et al., H. Pylori eradication failure (EF)—further treatment possibilities, Gastroenterology. (1992), 102:A43.
[cited by applicant]
Borody, T.J. et al., “Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection”; Aliment Pharmacology Therap. (2006) 23:481-488.
[cited by applicant]
Brogden, Rex N. et al., “A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy”, Drug Evaluation., Drugs (1994), 47:983-1009.
[cited by applicant]
Broutet, N. et al. “Risk factors for failure of Helicobacter pylori therapy—results of an individual data analysis of 2751 patients”, Aliment Pharmacol. Therap. (2003), 17:99-109.
[cited by applicant]
Burman, William et al., “Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis”, Am. J. Respir. Crit. Care Med. (2006), 173:350-356.
[cited by applicant]
Canducci, F. et al., “Rifabutin-based Helicobacter pylori eradication ‘rescue therapy’”, Aliment Pharmacol. Ther. (Jan. 2001), 15:143.
[cited by applicant]
Cardenas, Victor M. et al., “Iron deficiency and Helicobacter pylori infection in the United States”, Am. J. Epidemiology (2006), 163:127-134.
[cited by applicant]
Cardenas, Victor M. et al., Helicobacter pylori Eradication and Its Effect on Iron Stores: A Reappraisal, J. Infect. Dis. (2006), 194:714.
[cited by applicant]
Chey, William D. et al., “Noninvasive Helicobacter pylori testing for the “test-and-treat” strategy: A decision analysis to assess the effect of past infection on test choice”, Arch. Intern. Med. (2001), 161:2129-2132.
[cited by applicant]
Chey, William D. et al., “American College of Gastroenterology guideline on the management of Helicobacter pylori infection”, Am. J. Gastroenterol. (2007), 102:1808-1825.
[cited by applicant]
D'Elios, Mario M. et al., “Helicobacter pylori: usefulness of an empirical fourth-line rifabutin-based regimen”, Expert Rev. Gastroenterol Hepatol. (2012), 6:437-439.
[cited by applicant]
De Francesco, Vincenzo et al., Worldwide H. pylori Antibiotic Resistance: a Systematic Review, J. Gastrointestin. Liver Dis. (2010), 19:409-414.
[cited by applicant]
Dholakia, K.R. et al., “Vitamin B12 deficiency and gastric histopathology in older patients”, World J. Gastroenterol. (2005), 11(45):7078-7083.
[cited by applicant]
DuBois, Suja et al., “Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence”, Am. J. Gastroenterol. (2005), 100:453-459.
[cited by applicant]
Duck, William M. et al., “Antimicrobial resistance incidence and risk factors among Helicobacter pylori infected persons, United States”, Emerg. Infect. Dis. (2004), 10:1088-1094.
[cited by applicant]
Ekstrom, Anna Mia et al., “Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection”, Gastroenterology. (2010), 121(4):784-791.
[cited by applicant]
Fiorini, G. et al., “Culture-Based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for Helicobacter pylori Infection”, Clin. Gastroenterol. Hepatol. (Dec. 22, 2012), pil: S1542-3565(12)01507-8. …
[cited by applicant]
Ford, Alexander C. et al., “Epidemiology of Helicobacter pylori infection and Public Health Implications”, Helicobacter. (2010), 15 (Suppl. 1): 1-6.
[cited by applicant]
Gisbert, J.P. et al., “Review article: Helicobacter pylori ‘rescue’ regimen when proton pump inhibitor-based triple therapies fail”, Aliment Pharmacol. Ther. (2002), 16:1047-1057.
[cited by applicant]
Gisbert, J.P. et al., “Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regime after two Helicobacter pylori treatment failures”, Aliment Pharmacol. Ther. (2006), 24:1469-1474.
[cited by applicant]
Gisbert, J.P., “Rescue” regimens after Helicobacter pylori treatment failure, World J. Gastroenterol. (2008), 14 (35):5385-5402.
[cited by applicant]
Gisbert, J.P., “Rescue Therapy for Helicobacter pylori Infection 2012”, Gastroenterol Res. Pract. (2012a), epub. 974594.
[cited by applicant]
Gisbert, J.P. et al., “Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures”, Aliment Pharmacol. Ther. (2012c), 35(8):941-947.
[cited by applicant]
Glocker, Erik et al., “Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany”, Journal of Antimicrobial Chemotherapy. (2007), 59:874-879.
[cited by applicant]
Glupczynski, Y. et al., “Lack of antibiotic compliance in patients treated for Campylobacter pylori-associated gastritis”, Am. J. Gastroenterol. (1989), 84:1125-1126.
[cited by applicant]
Goddard, Andrew F. et al., “Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice”, Gastroenterology. (1996), 111:358-367.
[cited by applicant]
Godoy, Anita Paula Ortiz et al., “Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates”, BioMed Central, Gastroenterol. (2003), 11:3-20.
[cited by applicant]
Gonzalez, Pedro Carro et al., “Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments”, J. Gastroenterol. Hepatol. (2007), 22,60-63.
[cited by applicant]
Graham, David Y. et al., “Seroepidemiology of Helicobacter pylori infection in India, Comparison of developing and developed countries”; Dig. Dis. Sciences. (1991), 36:1084-1088.
[cited by applicant]
Graham, Kathleen S. et al., “Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection”, Am. J. Gastroenterol. (1995), 90:1415-1418.
[cited by applicant]
Graham, David Y., “Editorial: Can therapy ever be denied for Helicobacter pylori infection?”, Gastroenterology. (1997a), 113:S113-S117.
[cited by applicant]
Graham, David Y., “Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model”, Gastroenterology. (1997b), 113:1983-1991.
[cited by applicant]
Graham, David Y., “Efficient identification and evaluation of effective Helicobacter pylori therapies”, Clin. Gastroenterol Hepatol. (2009), 7:145-148.
[cited by applicant]
Graham, David Y. et al., “Clinical practice: diagnosis and evaluation of dyspepsia”, J. Clin. Gastroenterol. (2010a), 44:167-172.
[cited by applicant]
Graham, David Y., “Helicobacter pylori eradication therapy research: ethical issues and description of results”, Clin. Gastroenterol Hepatol. (2010b), 8:1032-1036.
[cited by applicant]
Graham, David Y. et al., “Helicobacter pylori therapy demystified”, Helicobacter. (2011), 16:343-345.
[cited by applicant]
Graham, David Y. et al., “Guide regarding choice of second-line therapy to obtain a high cumulative cure rate”, Helicobacter. (2012), 17:243-245.
[cited by applicant]
Grayson, M.L. et al., “Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents”, Eur. J. Clin. Microbiol. Infect. Dis. (1989), 8:888-889.
[cited by applicant]
Harford, William et al., “Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure off Helicobacter pylori infection”, Helicobacter (1996), 1:243-250.
[cited by applicant]
Heep, Markus et al., “Rifampin and rifabutin resistance mechanism in Helicobacter pylori”, Antimicrobial Agents and Chemother. (1999), 43:1497-1499.
[cited by applicant]
Kelleher, P. et al., “Uveitis associated with rifabutin and macrolide therapy for
[cited by applicant]
Kim, Jung Mogg et al., “Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients”, Int. J. Antimicrob Agents. (2006), 28:6-13.
[cited by applicant]
Kim, Seung Young et al., “Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea”, Br. J. Clin. Pharmacol. (2011), 73:1:140 143.
[cited by applicant]
Kita, Tomoko et al., “CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability”, Pharm. Res. (2001), 18:615-21.
[cited by applicant]
Kumala, Widyasari et al., “Patterns of Helicobacter pylori isolate resistance to fluoroquinolones, amoxicillin, clarithromycin and metronidazole”, Southeast Asian J. Trop Med Public Health. (2006), 37:970-974.
[cited by applicant]
Kunin, Calvin M., “Antimicrobial activity of rifabutin”, Clin. Infect Dis. (1996), 2 (Suppl 1) S3-14.
[cited by applicant]
Lee, Yi-Chia et al., “The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention”, Gut. (2013), 62(5):676-82, doi:10.1136/gutjnl-2012-302240, Epub. (Jun. 14, 2…
[cited by applicant]
Li, Albert P. et al., “Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine, and rifabutin”…
[cited by applicant]
Li, Jiehui et al., “Relapse and acquired rifampin resistance in HIV infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000”, Clin. Infect. Dis. (2005), 41:83-9…
[cited by applicant]
Luther, Jay et al., “Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability”, Am. J. Gastroenterol. (2010), 105:65-7…
[cited by applicant]
Maconi, Giovanni et al., “Predictors of long-term outcome of functional dyspepsia and duodenal ulcer after successful Helicobacter pylori eradication-a 7-year follow-up study”, European. J. Gastroenterol Hepatol. (2009)…
[cited by applicant]
Malfertheiner, P. et al., “Current European concepts in the management of helicobacter pylori infection—the Maastricht consensus report”, The European Helicobacter pylori study group (EHPSG) Eur. J. Gastroenterol Hepato…
[cited by applicant]
Malfertheiner, P., Management of H. pylori infection: Maastricht III—2005.
[cited by applicant]
Malfertheiner, Peter et al., “Guidelines for the Management of Helicobacter pylori Infection”, Business Review: European Gastroenterology Review (2005), 59-60, 998-999.
[cited by applicant]
Malfertheiner, P. et al., “Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a rand…
[cited by applicant]
Malfertheiner, Peter et al., “Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus report”, Gut. (2012), 61:646-664.
[cited by applicant]
Marshall, Barry J. et al., “Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori”, The Lancet. (Dec. 1988), 24/31, 2 (8626-8627):1437-1342.
[cited by applicant]
Marshall, B. J., “Treatment strategies for Helicobacter pylori infection”, Gastroenterol Clin. North Am. (1993), 22:183-198.
[cited by applicant]
Mcnulty, Cliodna A. M. et al., “Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate”, British Medical Journal (1986), 293:…
[cited by applicant]
Megraud, F., “H pylori antibiotic resistance: prevalence, importance, and advances in testing”, Gut. (2004), 53:1374-1384.
[cited by applicant]
Megraud, Francis et al., “Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption”, Gut. (2013), 62:34-42.
[cited by applicant]
Miehlke, S. et al., “Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin”, Aliment Pharmacol. Ther…
[cited by applicant]
Miehlke, Stephan et al., “One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin”, Helicoba…
[cited by applicant]
Moayyedi, P. et al., “Eradication of Helicobacter pylori for non-ulcer dyspepsia (Review)”, The Cochrane Database of Systematic Reviews. (2006), 2:1-40.
[cited by applicant]
MYCOBUTIN® (rifabutin) Capsules, Package Insert, (Jan. 2010), Pharmacia and Upjohn Company.
[cited by applicant]
Navarro-Jarabo, Jose M. et al., “Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate Helicobacter pylori infection”, BioMed Central, Gastroenterol. (2007), 7:31.
[cited by applicant]
NCI. Surveillance Epidemiology and End Results, SEER Stat Fact Sheet: Stomach, http://seer.cancer.gov/statfacts/html/stomach.html, Accessed Mar. 2013.
[cited by applicant]
Oderda, G. et al., “Campylobacter pylori gastritis: long term results of treatment with amoxycillin”, Arch. Dis. Child. (1989), 64:326-329.
[cited by applicant]
OMECLAMOX-PAK™ (omeprazole, clarithromycin, amoxicillin) Kit, Package Insert, (Feb. 2012), Pernix Therapeutics.
[cited by applicant]
Perri, A. et al., “ Treatment of antibiotic-resistant Helicobacter pylori Infection”, The New England Journal of Medicine (1998), 33:53.
[cited by applicant]
Perri, F. et al., “Rifabutin-based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens”, Aliment Pharmacol. Ther. (2000), 14:311 316.
[cited by applicant]
Perri, Francesco et al., “Randomized study of two “rescue” therapies for Helicobacter pylori-infected patients after failure of standard triple therapies”, Am. J. Gastroenterol. (2001), 96:58-62.
[cited by applicant]
Perucca, E. et al., Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects, Eur. J. Clin. Pharmacol. (1988), 34:595 599.
[cited by applicant]
PREVPAC® (lansoprazole, amoxicillin and clarithromycin) Kit, Package Insert, (Oct. 2009), Takeda Pharmaceuticals America.
[cited by applicant]
PRILOSEC® (omeprazole) Delayed-Release Capsules and PRILOSEC® (omeprazole magnesium) for Delayed-Release Oral Suspension, Package Insert, (May 2013), AstraZeneca.
[cited by applicant]
PROTONIX® (pantoprazole sodium) Tablet, Delayed Release and PROTONIX® (pantoprazole sodium) Granule, Delayed Release, Package Insert, (Oct. 2012), Wyeth.
[cited by applicant]
Qasim, Asghar et al., “Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients”, Aliment Pharmacol. Ther. (…
[cited by applicant]
Reinach, Benedetta et al., “Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP- glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes”, Chem. Biol. Interact. (1999), …
[cited by applicant]
Rimbara, Emiko et al., “Optimal therapy for Helicobacter pylori infections”, Nature Reviews Gastroenterology & Hepatology (2011), 8:79-88.
[cited by applicant]
Ronchera, C. L. et al., “Pharmacokinetic interaction between high-dose methotrexate and amoxicillin”, Ther. Drug Monit. (1993), 15:375-379.
[cited by applicant]
Salazar, Cesar O. et al., “Greater than 95% success with 14-day bismuth quadruple anti-Helicobacter pylori therapy: a pilot study in US Hispanics”, Helicobacter. (2012), 17:382-390.
[cited by applicant]
Salcedo, Julio A. et al., “Treatment of Helicobacter pylori infection”, Arch. Intern. Med. (1998), 158:842-851.
[cited by applicant]
Schwartz, H. et al, “Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in d…
[cited by applicant]
Selgrad, Michael et al., “Clinical Aspects of Gastric Cancer and Helicobacter pylori—Screening, Prevention, and Treatment”, Helicobacter, (2010), 15 (Suppl. 1), 40-45.
[cited by applicant]
Shafran, Stephen D. et al., “A comparison of two regimens for the treatment of
[cited by applicant]
Shirai, Naohito et al., “Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the…
[cited by applicant]
Suzuki, Shoji et al., “Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori”, Digestion. (2009), 79:1-4.
[cited by applicant]
Talley, Nicholas J., “Guidelines for the management of dyspepsia”, Am. J. Gastroenterol. (2005), 100:2324-2337.
[cited by applicant]
Thyagarajan, S.P., et al., “Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study”, J. Gastroenterol. Hepatol. (2003), 18:1373-1378.
[cited by applicant]
Toracchio, S. et al., “Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin”, Dig. Liver. Dis. (2005), 37:33-38.
[cited by applicant]
Tseng, Alice L. et al., “Rifabutin-associated uveitis”, Ann. Pharmacother. (1995), 29:1149-1155.
[cited by applicant]
Tsuchiya, Mamiko et al., “Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor”, Biol. Pharm. Bull. (Aug. 1995), 18 (8):1053-1056.
[cited by applicant]
Unge, P. et al., “Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis?”, A pilot study. Scand. J. Gastroenterol. Suppl. (1989), 167:49-54.
[cited by applicant]
Van Der, Poorten D. et al. “The effectiveness of rifabutin triple therapy for patients with difficult to eradicate Helicobacter pylori in clinical practice”, Aliment Pharmacol. Ther. (2007), 26:1537-1542.
[cited by applicant]
Walsh, John H. et al., “The treatment of Helicobacter pylori infection in the management of peptic ulcer disease”, New Eng. J. Med. (1995), 333:984-991.
[cited by applicant]
Wannmacher, Lennita, “Review of the evidence for H. pylori treatment regimens”, Section 17.1 (Review)—Adults and Children. 18th Expert Committee on the Selection and Use of Essential Medicines. (2011), World Health Orga…
[cited by applicant]
World Health Organization, “Treatment of Tuberculosis Guidelines”, 4th edition (2010), 85.
[cited by applicant]
Wong, B. C. Y. et al., “Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study”, Alime…
[cited by applicant]
Wong, W. M. et al., “Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection”, Aliment. Pharmacol. Ther. (20…
[cited by applicant]
PCT International Search Report and the Written Opinion of the International Searching Authority dated May 16, 2014 (11 pages).
[cited by applicant]
Blaschke, Terrence F. et al., “The Clinical Pharmacokinetics of Rifabutin”, Clinical Infectious Diseases, 1996: 22 (Suppl. 1):S15-22.
[cited by applicant]
Gisbert, J. P. et al., “Review Article: Rifabutin in the Treatment of Refractory Helicobacter Pylori Infection”, Aliment Pharmacal. Ther. 2012, www.medscape.com, 35(2), p. 209-221.
[cited by applicant]
Dubois, Andre et al., “Transient and Persistent Experimental Infection of Nonhuman Primates with Helicobacter Pylori: Implications for Human Disease”, Infection and Immunity, Aug. 1996, p. 2885-2891.
[cited by applicant]
Tariq et al. (Reevalution of the Efficacy of First Line Regimen for Helicobacter pylori) Jan. 2020.
[cited by applicant]